With EpiPen price-gouging in the news, Columbia's School of Professional Studies Bioethics Program Director, Dr. Robert Klitzman, has a new op-ed in CNN about the ethical questions raised by drug companies' overcharging patients. It's a tangled story of the principles of medicine, the profit priorities of private companies, and the taxpayers' money that creates these innovations.
Faculty - August 30, 2016
Robert Klitzman on EpiPen's Price Hike
Related NewsAll News
The Future of Work: Culture, Collaboration and Other ‘Intangibles’
A July 22 Information & Knowledge Strategy Proseminar spotlights culture-building at software company ServiceNow.
Dr. Solange Charas Discusses Human Capital Analytics with Engagement Strategies Media
Dr. Charas on how to apply analytics-based decisions across an organization.